TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03292705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEP
Description: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCI
Description: VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCI
Description: VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
Study: NCT01439620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH Optical Frequency Domain Imaging (OFDI)
Description: Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
Study: NCT04967469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
Study: NCT00255814

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT04967469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 MCG Oral Capsule
Description: end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
Study: NCT03513185

Intervention type: DRUG
Intervention: Deanxit, SSRI or SRNI
Description: After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
Study: NCT01418222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT02610647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapping test
Description: Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapping test
Description: Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapping test
Description: Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail.
Study: NCT01426568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Convergent Therapy
Description: Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
Study: NCT01026402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
Study: NCT02241577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
Study: NCT00584753

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography and computed tomography
Description: Positron emission tomography and computed tomography

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography and computed tomography
Description: Positron emission tomography and computed tomography

Intervention type: RADIATION
Group type: OTHER
Intervention: Positron emission tomography and computed tomography
Description: Positron emission tomography and computed tomography
Study: NCT01015573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic sensor system to measure the movements of finger tapping
Study: NCT04123379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: 300mg oral twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: 300mg oral twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: 2400mg once by injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: 2400mg once by injection
Study: NCT04261712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, once daily by mouth
Study: NCT01017120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Tazarotene foam once a day application to the face

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam once a day application to the face
Study: NCT02392858

Intervention type: OTHER
Group type: OTHER
Intervention: influenza cohort
Description: Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
Study: NCT01418222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onartuzumab [MetMAb]
Description: Intravenous repeating dose
Study: NCT03844516

Intervention type: OTHER
Group type: OTHER
Intervention: Peak oxygen uptake test with pacing
Description: Peak oxygen uptake test with paced heart rate

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Peak oxygen uptake test without pacing
Description: Peak oxygen uptake test without paced heart rate
Study: NCT02702258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP
Description: MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
Study: NCT02338713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcium 500 mg and vitamin D3 1000 IU chewable tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noncarbonated Water
Description: Noncarbonated water 200 mL
Study: NCT04173663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASSIST
Description: The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
Study: NCT01565018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.1.4
Description: Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.1.4
Description: Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
Study: NCT00401583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034 (pazopanib)
Description: Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
Study: NCT01565018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.2.1
Description: Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.2.1
Description: Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
Study: NCT00333788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CDP870)
Description: 400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
Study: NCT00401583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe drugs
Description: probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
Study: NCT00593112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Description: Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
Study: NCT01813864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASPAR/Treatment Planning
Description: All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
Study: NCT03708133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Test
Description: Orally intake of 1 \*120mg new formulation tablet as test treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Test
Description: Orally intake of 1 \*120mg new formulation tablet as test treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Reference
Description: Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Reference
Description: Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
Study: NCT01927016

Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
Study: NCT03967262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
Study: NCT01049581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: two hours per week, one hour per time, total 12 weeks
Study: NCT04367142

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral

Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral
Study: NCT01261767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
Study: NCT03092960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal intensity intervention
Description: The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOMBRE
Description: HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
Study: NCT00252928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets
Description: Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01406860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide + diphenhydramine
Description: Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
Study: NCT02391285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamometer (Auckland vaginal elastometer)
Description: The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings.